Jefferies⬆️the PT on $ATYR to $17 from $9, reiterated at Buy and Provided its Base (plus 1-3X), Bull (plus 3-5X) and Bear (up to -75%+) Case Scenarios ahead of mid-Sept Efzofitimod Ph3 topline data.
Jefferies⬆️the PT on $ATYR to $17 from $9, reiterated at Buy and Provided its Base (plus 1-3X), Bull (plus 3-5X) and Bear (up to -75%+) Case Scenarios ahead of mid-Sept Efzofitimod Ph3 topline data.
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewswire https://t.co/vwmGiZQLg9
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewswire https://t.co/vwmGiZQdqB
H.C. Wainwright reit $ATYR Buy/$35, after the Foundation for Sarcoidosis Res hosted a Patient-Focused Drug Development meeting as a forum4sarcoidosis pts, caregivers/Tx'g MD's 2 discuss current unmet needs, the QoL impacts of sarcoidosis/preferences w/ respect2 devt of new Tx's:
Un desarrollador de Bitcoin argumenta que cualquier cambio en el suministro fijo de Bitcoin, aunque teóricamente posible, ya no se consideraría "Bitcoin".
Fuente: Cointelegraph https://t.co/JwG47K0enR